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Single nucleotide polymorphisms (SNPs) within the
ADCY5 gene, encoding adenylate cyclase 5, are associ-
ated with elevated fasting glucose and increased type 2
diabetes (T2D) risk. Despite this, the mechanisms un-
derlying the effects of these polymorphic variants at
the level of pancreatic b-cells remain unclear. Here,
we show ﬁrstly that ADCY5 mRNA expression in islets
is lowered by the possession of risk alleles at rs11708067.
Next, we demonstrate that ADCY5 is indispensable for
coupling glucose, but not GLP-1, to insulin secretion in
human islets. Assessed by in situ imaging of recombinant
probes, ADCY5 silencing impaired glucose-induced cAMP
increases and blocked glucose metabolism toward
ATP at concentrations of the sugar >8 mmol/L. However,
calcium transient generation and functional connectivity
between individual human b-cells were sharply inhibited
at all glucose concentrations tested, implying addi-
tional, metabolism-independent roles for ADCY5.
In contrast, calcium rises were unaffected in ADCY5-
depleted islets exposed to GLP-1. Alterations in b-cell
ADCY5 expression and impaired glucose signaling
thus provide a likely route through which ADCY5 gene
polymorphisms inﬂuence fasting glucose levels and
T2D risk, while exerting more minor effects on incretin
action.
Type 2 diabetes (T2D) is one of the foremost health
challenges currently facing developed societies. This
metabolic disease, which affects ;8.3% of the adult
population worldwide (1), usually reﬂects a failure of the
b-cell mass to adapt output to increased peripheral insulin
resistance. The resulting hyperglycemia and dyslipidemia
lead to debilitating complications, ranging from kidney fail-
ure and blindness to cardiovascular disease and cancer (2).
Although the maintenance of an adequate functional b-cell
mass is critical for avoiding the development of diabetes
(3), the molecular basis of b-cell failure is still poorly un-
derstood (4).
The mechanisms underlying glucose-stimulated insulin
secretion from single b-cells involve uptake of the sugar
via speciﬁc glucose transporters (5), enhanced ATP syn-
thesis (6), and closure of ATP-sensitive K+ (KATP) channels
(7). The consequent plasma membrane depolarization
leads to Ca2+ inﬂux (8) and exocytosis from secretory
granules (9), both of which are further potentiated by
“KATP-independent” amplifying signals (10). In addition,
incretin hormones such as glucagon-like peptide 1 (GLP-1)
and glucose-dependent insulinotropic peptide, released
in response to food transit through the gut, potentiate
insulin secretion in a glucose-dependent manner (11).
Cognate receptor activation engages adenylate cyclases
(ADCYs), enzymes that catalyze the generation of cAMP, a
key intra- and intercellular signaling effector in the b-cell.
Through its downstream interactions with protein kinase A
and exchange protein activated by cAMP (Epac), cAMP
drives changes including Ca2+ inﬂux, intracellular Ca2+ mo-
bilization (12), and the enhanced fusion competence of
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secretory granules (13). By contrast, glucose evokes more
modest increases in intracellular cAMP (14), possibly via
the stimulation of Ca2+-activated ADCYs such as ADCY1
and ADCY10 (15).
Both genetic (16) and environmental (4) risk factors
conspire to determine the rate and extent of loss of in-
sulin secretory capacity in T2D. Thus, the majority of
genetic risk loci (;70) currently identiﬁed by genome-
wide association (GWAS) or familial studies alter func-
tional b-cell mass while exerting little, or occasionally
a beneﬁcial, effect on insulin sensitivity (17). Of note,
recent genetic studies have provided evidence that several
pathways converging on b-cell cAMP signaling may inﬂu-
ence T2D risk. For example, carriers of the major A-allele
at rs11708067, or the C-allele at the neighboring single
nucleotide polymorphism (SNP) rs2877716, lying on chro-
mosome 3 in intron 3 of the ADCY5 gene, have an in-
creased odds ratio of developing T2D (18). ADCY5 is a
Ca2+-inhibited type III adenylate cyclase (19,20), and risk
allele carriers present with elevated fasting glucose (21) but
not impaired insulinogenic index or area under the curve
(AUC)insulin/glucose 2-h postoral glucose load (22–25). These
data strongly imply that ADCY5 activity may be required
for normal insulin release in response to glucose but not
incretin, the latter largely accounting for the effects of oral
glucose (26). Whether and how SNPs exert control over
b-cell function by inﬂuencing ADCY5 expression remain,
nonetheless, unclear.
Therefore, the aims of the current study were to 1)
establish a link between genotype and ADCY5 mRNA lev-
els, 2) silence ADCY5 expression in human islets using
speciﬁc short hairpin (sh)RNAs, and 3) use in situ imaging
approaches and hormone release assays to establish the
role of the cyclase in regulating b-cell responsiveness to
glucose and incretin.
RESEARCH DESIGN AND METHODS
Human Islet Isolation
Human islets were isolated from deceased heart-beating
donors at transplantation facilities in Oxford, Geneva,
Pisa, Edmonton, and Milan, with the relevant national
and local ethics permissions, including consent from next
of kin where required, and cultured as described (27). All
studies involving human tissue were approved by the Na-
tional Research Ethics Committee (NRES) London (Fulham),
Research Ethics Committee no. 07/H0711/114.
Mouse Islet Isolation
Male and female C57BL/6 mice, 8–12 weeks of age, were
killed by cervical dislocation and pancreatic islets isolated
by collagenase digestion as previously described (28). An-
imal procedures were approved by the home ofﬁce accord-
ing to the Animals (Scientiﬁc Procedures) Act 1986 of the
United Kingdom (PPL 70/7349).
ADCY5 Genotyping
DNA samples were genotyped for the SNP rs11708067
by restriction fragment length polymorphism analysis, as
the G allele generated an HhaI site. A 250-bp region ﬂank-
ing the locus was ampliﬁed by PCR using Phire polymerase
(Thermo) with the following primers: TCCGGAAGGCAAA
CACAGCA and AGCCAGGCTGCACCCAAGTG. The prod-
ucts were digested with HhaI and resolved by agarose gel
electrophoresis.
Lentiviral Delivery of shRNA
Lentiviral particles carrying shRNA expression constructs
against human ADCY5 were acquired from Sigma-Aldrich
(Supplementary Table 1). Multiplicity of infection was
calculated using Turbo-GFP particles on the same back-
bone (TRC 1.5; Sigma-Aldrich). Speciﬁcity of ADCY5
gene silencing was conﬁrmed in both dissociated and
intact islets, assuming 1,000–2,000 cells/islet for the
latter. In all cases, lentiviral particles containing scram-
bled shRNA were used as controls (Con) and islets
infected for 48–72 h.
Generation of Adenoviral Epac2-camps
cDNA encoding the cAMP sensor citrine/cerulean-Epac2-
camps (29) was cloned into pShuttleCMV via HindIII and
Xho1 sites before recombination with pAdEasy1 and virus
production as described (6,30).
Real-Time PCR
Relative mRNA abundance was quantiﬁed by quantitative
RT-PCR (qRT-PCR) using SYBR green (31). Primers (Sup-
plementary Table 2) were designed using PerlPrimer (32),
speciﬁcity validated using a dissociation curve, and ampli-
ﬁcation efﬁciency was determined using a dilution series.
Expression of each gene was normalized to cylcophilin A
(Ppia) and N-fold change in mRNA expression versus Con
calculated using the 22DDCt.
ADCY5 mRNA levels were measured for expression
quantitative trait locus analysis by qRT-PCR of RNA from
isolated human islets as described earlier (33). The ex-
pression level of ADCY5 relative to TATA box–binding
protein (TBP) was determined by qRT-PCR using Taqman
primers and reagents (Supplementary Table 3) and the
comparative Ct method (22DDCT) used for subsequent
calculations.
Immunohistochemistry
Islets were ﬁxed overnight at 4°C in paraformaldehyde
before application of primary antibodies against ADCY5/
6 (cat. no. ab66037; Abcam) (34) and either guinea pig
anti-insulin 1:200 or mouse anti-glucagon 1:1,000 (both
DAKO). Revelation was performed with goat anti-rabbit
Alexa-Fluor 488 and either goat anti–guinea pig Alexa-
Fluor 568 or goat anti-mouse Alexa-Fluor 568 antibodies
(both 1:500, Invitrogen). Images were acquired as previ-
ously described (27).
Measurements of Insulin Secretion From Isolated
Islets
Insulin secretion was measured from groups of ﬁve to six
islets per well, incubated for 30 min in 0.5 mL Krebs-
HEPES-bicarbonate (KHB) solution (130 mmol/L NaCl,
3.6 mmol/L KCl, 1.5 mmol/L CaCl2, 0.5 mmol/L MgSO4,
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0.5 mmol/L NaH2PO4, 2 mmol/L NaHCO3, 10 mmol/L
HEPES, and 0.1% [w/v] BSA, pH 7.4) at 37°C containing
the indicated glucose and GLP-1 (7-36 human amide frag-
ment) (Cambridge Bioscience) concentrations (35). Total
islet proinsulin and insulin were measured after acid eth-
anol extraction and sonication using speciﬁc radioimmu-
noassays (EMD Millipore).
Live:dead and TUNEL Assays
Islets were incubated with 3 mmol/L calcein-AM (Life
Technologies) and 2.5 mmol/L propidium iodide (Sigma-
Aldrich) before detection of absorbance/emission at 491/
525 nm and 561/620 nm, respectively. The islet area
occupied by dead cells was expressed as a unitary ratio
versus that occupied by live cells. Apoptosis was assessed
using a TUNEL staining kit (Promega) according to the
manufacturer’s instructions, and islets were counter-
stained against insulin before detection of absorbance/
emission at 491/525 nm and 561/620 nm, respectively.
Calcium, ATP/ADP, and cAMP Imaging
Isolated islets were incubated (37°C, 95% O2/5% CO2) for
1 h in ﬂuo2-AM (10 mmol/L) diluted in a bicarbonate
buffer solution (120 mmol/L NaCl, 4.8 mmol/L KCl,
1.25 mmol/L NaH2PO4, 24 mmol/L NaHCO3, 2.5 mmol/L
CaCl2, 1.2 mmol/L MgCl2, and 3 mmol/L D-glucose; all
Sigma-Aldrich). Functional multicellular Ca2+ imaging was
performed using a Nipkow spinning-disk head and the
resulting traces were normalized to minimum ﬂuorescence
(Fmin) (27). A near-identical distribution of Fluo-2 in-
tensity was detected in Con and ADCY5 shRNA-treated
islets under resting (3 mmol/L glucose) conditions, in-
dicating that basal Ca2+ levels were likely unaffected by
gene knockdown, assuming similar dye loading (Supple-
mentary Fig. 1).
For imaging of cytosolic ATP/ADP with Perceval (6) or
cAMP with Epac2-camps, islets were infected for 48 h
with adenoviruses at multiplicity of infection 10–100,
giving infection of the ﬁrst 2–3 islet cell layers. Cells were
imaged using a HEPES-bicarbonate buffer (120 mmol/L
NaCl, 4.8 mmol/L KCl, 24 mmol/L NaHCO3, 0.5 mmol/L
Na2HPO4, 5 mmol/L HEPES, 2.5 mmol/L CaCl2, and 1.2
mmol/L MgCl2). For Perceval, absorbance/emission was
491/525 nm. For the Epac2-camps probe, excitation was
delivered at 440 nm and emitted signals captured using
cerulean (530 nm) and citrine (470 nm) ﬁlters. Förster
resonance energy transfer (FRET) was calculated as the
ratio of cerulean:citrine ﬂuorescence and, for each experi-
ment, expressed as a percentage of that obtained after
maximal stimulation with 50 mmol/L forskolin (FSK). No
differences in probe responses to FSK were detected in Con
and ADCY5 shRNA-treated tissue (F/Fmin = 1.07 6 0.01
vs. 1.06 6 0.01 arbitrary units [AU], Con vs. ADCY5, re-
spectively; P . 0.05).
ZIMIR Imaging
ZIMIR, a membrane-bound probe that ﬂuoresces upon
binding of zinc (Zn2+) coreleased with insulin from gran-
ules, was used to dynamically monitor insulin secretion as
previously described (27,36). Brieﬂy, islets were incubated
with 10 mmol/L ZIMIR for 2 h and imaged in bicarbonate
buffer supplemented with 1 mmol/L EGTA. After acquisition
(absorbance/emission = 491/525 nm), islets were divided
into 20 subregions before extraction of intensity over
time traces and analysis of amplitude and AUC.
Total Internal Reﬂection of Fluorescence Microscopy
Insulin-stained PFA-ﬁxed islets were subjected to total
internal reﬂection of ﬂuorescence imaging to capture a
superresolution snapshot of submembrane insulin gran-
ule distribution. The evanescent ﬁeld was produced using
a 561-nm laser (CrystaLaser) and a 1003 1.6 NA objective
(Zeiss). Insulin granule density was expressed as a unitary
ratio versus the total membrane area, the latter being
clearly visible between adjacent cells.
Correlation and Frequency Analysis
Correlation and frequency analyses were performed as
previously detailed (27,37). Brieﬂy, intensity over time
traces were extracted for each ﬂuo-2–loaded cell using
a region of interest before manual triage for glucose re-
sponsiveness based on rises above a 25% threshold. The
Pearson product moment correlation was performed for
all possible cell pair combinations and signiﬁcance (P ,
0.05) calculated versus the expected t distribution of in-
dependent R values. Functional connectivity maps show-
ing the location of signiﬁcantly correlated cell pairs were
then constructed based upon correlation strength and
position within the imaged ﬁeld (x–y). Phase maps were
compiled by converting the normalized intensity of each
cell to a value between 1 and 100% and assigning this to
a color using a light-dark ramp. Ca2+-spiking frequency
was measured using the fast Fourier transform.
Statistical Analysis
Data distribution was determined using D’Agostino omni-
bus or Shapiro-Wilk tests. Nonmultifactorial pairwise com-
parisons were made using Mann-Whitney U test or Student
unpaired and paired t tests. Two-way ANOVA was used to
assess interactions between multiple treatments (P ,
0.01), and pairwise comparisons were performed using
Bonferonni posttests. Expression quantitative trait locus
data were stratiﬁed according to genotype, BMI, age, and
sex. Factors included in the model were selected using the
Akaike Information Criterion, resulting in the exclusion of
age and BMI, as these were uninformative with regard to
ADCY5 expression. To account for any prediction error,
linear regression analyses were performed separately for
both excluded variables, yielding nonsigniﬁcant relation-
ships (P . 0.05). Owing to a signiﬁcant interaction be-
tween sex and genotype in donors 22–70 years of age
(P = 0.0476; two-way ANOVA), effects of genotype on
mRNA abundance were assessed within sex group using
one-way ANOVA. In all cases, analysis was performed using
R (R Project), GraphPad Prism (GraphPad Software), IgorPro
(Wavemetrics), and MATLAB (Mathworks), and results
were considered signiﬁcant at P , 0.05.
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RESULTS
ADCY5 Is Expressed in Human Islets at the mRNA and
Protein Level
We sought ﬁrstly to characterize ADCY5 expression in
tissue isolated from human and murine donors. Conﬁrm-
ing previously published microarray data (33), SYBR Green
qRT-PCR analyses revealed that ADCY5 and ADCY6 tran-
script levels were similar in human but not mouse islets
(Fig. 1A). Immunohistochemistry using an antibody against
ADCY5, and with some reported cross-reactivity against
ADCY6, demonstrated the localization of both enzymes
in the cytoplasm of insulin and glucagon immunopositive
cells throughout individual human islets (Fig. 1B).
ADCY5 mRNA Levels Are Inﬂuenced by Genotype
While GWAS provides statistically powerful information
concerning associations between SNPs and T2D risk, it
is unable to report on how the expression of genes at
variant loci is altered in tissues implicated in glucose
homeostasis. Since the elevated glucose levels associated
with T2D may inﬂuence ADCY5 expression, we attempted
to correlate genotype at SNP rs11708067 with ADCY5
mRNA abundance using tissue from a catalog of healthy
donors. Allele frequency was close to that expected from
previous studies (;75% A) (18), and Taqman qRT-PCR
analysis of RNA from isolated islets revealed approximately
twofold lower mean ADCY5 expression in male AA versus
AG carriers ,70 years of age (Fig. 1C and Supplementary
Table 4). When considered separately, neither age nor BMI
signiﬁcantly inﬂuenced ADCY5 expression for either geno-
type (Fig. 1D and E).
ADCY5 Is Required for Glucose-Stimulated Insulin
Secretion
Given the above association between ADCY5 expression
and fasting glucose levels and genotype in man, we next
explored a role for this gene in human b-cell stimulus-
secretion coupling. shRNAs directed against various
sequences of the ADCY5 gene were delivered into dispersed
cells or islets using replication-incompetent lentiviruses
(n = 26 separate normoglycemic donors) (see Supplemen-
tary Table 5). Gene silencing efﬁciency was determined
using qRT-PCR (Fig. 2A and B), and effects were conﬁrmed
at the protein level using immunohistochemistry and an
antiserum raised against ADCY5/6 (Fig. 2C). Although mRNA
levels were less affected by shRNA in intact than dissoci-
ated islets, this was most likely due to limited penetration
of virus into the islet core (38); cells within the imaged
layers were nevertheless typiﬁed by the near-complete ab-
sence of ADCY5 immunoreactivity. ADCY6 mRNA abun-
dance was not altered by ADCY5 silencing, suggesting that
the action of the shRNA on immunoreactivity was largely
due to loss of the latter mRNA message (Fig. 2D). Cell vi-
ability and apoptosis indices were normal, excluding any
effects of impaired cAMP signaling on b-cell survival (Fig.
2E and F).
The impact of ADCY5 silencing on glucose- or incretin-
stimulated insulin secretory dynamics was subsequently
Figure 1—ADCY5 is expressed in isolated human islets and affected
by T2D risk alleles. A: ADCY5 and ADCY6 are expressed at similar
levels in human islets (n = 4 donors). Conversely, Adcy6 mRNA ex-
pression is;40-fold more abundant than that of Adcy5, which is barely
detectable in mouse islets (n = 3 female and 3 male animals; **P< 0.01
vs. ADCY5, Student t test). B: Immunostaining using an anti-ADCY5
immunoglobulin, with some reported cross-reactivity to ADCY6,
reveals the cytoplasmic distribution of both proteins throughout the
human a- and b-cell populations (DAPI, blue; scale bar, 60 mm). C:
Scatter plot showing reduced ADCY5 mRNA abundance in islets from
males <70 years of age who are carriers of the AA risk allele at
rs11708067 (*P < 0.043 vs. AG; one-way ANOVA; n = 7 donors for
each allele). Values represent mean 6 SEM. D: Age of donors is not
signiﬁcantly correlated with ADCY5 mRNA expression (R2 = 0.21 and
R2 = 0.01 for AG and AA, respectively; linear regression) (P values
shown on graph). E: As for D, but BMI (R2 = 0.23 and R2 = 0.003,
AG vs. AA, respectively; linear regression) (P values shown on graph).
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Figure 2—ADCY5 silencing inhibits glucose- but not GLP-1–stimulated insulin secretion. A and B: Lentivirus harboring shRNA against
ADCY5 reduces expression by >50% in both dispersed and intact islets (**P < 0.01 vs. Con; Student paired t test; n = 3–4 donors). C:
ADCY5/6 protein expression is markedly reduced in the ﬁrst few cell layers of intact islets, as determined using confocal imaging (n = 6
islets from two donors). D: ADCY6 mRNA expression is unaffected by ADCY5 silencing (NS, nonsigniﬁcant vs. Con; Student paired t test;
n = 4 donors). E: Dead:live cell ratio is similar in Con and shRNA-treated islets (positive Con, Triton X-100; NS, nonsigniﬁcant vs.; Mann-
Whitney U test; n = 10–11 islets from three donors). F: As for E, but TUNEL assay for apoptosis (n = 9 islets from three donors). The proportion
of apoptotic b-cells was expressed as a fraction area versus nonapoptotic insulin-positive cell mass (Vv). G: ADCY5 knockdown suppresses
glucose-induced insulin secretory dynamics, as shown by bar graphs of AUC and amplitude of ZIMIR responses (mean traces, left panel; n =
8–9 islets from four donors) (**P < 0.01 vs. Con; Mann-Whitney U test). H: GLP-1–stimulated insulin secretory dynamics are subtly improved
after ADCY5 depletion (mean traces, left panel; AUC and amplitude, right panel; n = 7 islets from three donors) (NS, nonsigniﬁcant). I: Glucose-
stimulated insulin release into static culture is impaired in shRNA-treated islets, as determined using radioimmunoassay (G3 and G16.7,
3 mmol/L and 16.7 mmol/L glucose, respectively) (n = 4–8 donors). KCl 30 mmol/L was added as a Con. J: As for I, but stimulation index vs.
3 mmol/L glucose to better account for the variation between islet preparations (*P < 0.02 vs. Con at 16.7 mmol/L glucose; Mann-Whitney
U test). K: As for J, but vs. 16.7 mmol/L glucose (G16.7) (*P < 0.01 vs. 16.7 mmol/L glucose for each group; Mann-Whitney U test). Values
represent mean 6 SEM. hr, hour.
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assessed using Nipkow spinning-disk microscopy (27) to
image Zn2+ coreleased from insulin-containing granules
within individual ZIMIR-stained islets (27,36). The ampli-
tude and AUC of glucose (11 mmol/L)-stimulated insulin
release were markedly impaired in islets silenced for
ADCY5 (Fig. 2G). By contrast, insulin-release dynamics in
response to GLP-1 were subtly improved in tissue depleted
for ADCY5, suggesting the presence of an intact incretin
axis (Fig. 2H). The observations with ZIMIR were con-
ﬁrmed using conventional static incubation techniques
followed by radioimmunoassay of supernatant, and we fur-
ther detected no signiﬁcant effect of gene silencing on KCl-
stimulated insulin release (Fig. 2I–K). Donor variability was
largely accounted for by a paired experimental design, and
this was further supported by linear regression analyses,
which revealed no relationship between age, BMI, and the
magnitude suppression of glucose-stimulated insulin re-
lease in ADCY5-silenced islets (Supplementary Fig. 2).
Insulin content was similar in Con and ADCY5 shRNA-
treated islets, although there was a tendency toward an
increased proinsulin-to-insulin ratio in the latter (Table
1), as expected from studies in patients harboring SNPs
in or near the ADCY5 locus (25). Lastly, and in line with
the secretory measures, total internal reﬂection of ﬂuores-
cence imaging of insulin-stained islets conﬁrmed that
ADCY5 knockdown did not alter the distribution of gran-
ules located in the vicinity of the plasma membrane (Sup-
plementary Fig. 3A and B).
ADCY5 Couples Glucose to cAMP Generation,
Ca2+ Rises, and b-Cell Connectivity
Using Epac2-camps (29) to measure cAMP rises in b-cells
(Supplementary Fig. 4), almost a threefold reduction in
glucose- but not FSK-stimulated cAMP generation could
be detected in ADCY5-silenced islets (Fig. 3A and B). Since
cAMP elevations are linked to enhanced electrotonic cou-
pling (39), the effects of ADCY5 depletion on the cell-cell
communication processes underlying the intraislet regu-
lation of insulin secretion were next investigated. Cyto-
solic free Ca2+ levels were thus used as a proxy to measure
the electrical dynamics known to orchestrate Ca2+-dependent
hormone secretion from the hundreds of cells residing
within the ﬁrst few microorgan layers; under the condi-
tions used, Ca2+ changes chieﬂy reﬂect those within b-cells
(27). In line with its dramatic effects on secretion, ADCY5
silencing suppressed both the amplitude and AUC of glu-
cose-evoked Ca2+ rises throughout the imaged population
(Fig. 3C–E and Supplementary Movies 1 and 2) (n = 3 donors;
BMI range = 25.4–27.4; age range = 52–76 years). Further-
more, connectivity between individual b-cells, analyzed by
large-scale mapping of long-term (;30 min) evolutions in
correlated cell-cell interactivity (40) and recently shown to
be a key element in the insulin secretory response (27,41),
was also reduced in ADCY5-silenced islets (Fig. 3F and G).
Neither the number of responsive cells (Fig. 3H) nor the
frequency of [Ca2+]i oscillations (Fig. 3I) was affected by
ADCY5 knockdown, suggesting that the absence of the
cyclase was unlikely to impair insulin release by targeting
the rhythmicity of a b-cell subpopulation. Implying that
the effects of silencing were unlikely to reﬂect a long-
term consequence of ADCY5 depletion, a similar degree
of suppression of glucose-induced Ca2+ rises was ob-
tained using 20 mmol/L NKY80, a relatively selective
chemical inhibitor of the enzyme (IC50 = 8.3 mmol/L,
132 mmol/L, and 1.7 mmol/L for ADCY5, 3, and 2, re-
spectively) (42) (Supplementary Fig. 5A). Demonstrating
the speciﬁcity of both shRNA and NKY80, the inhibitory
actions of the drug were lost after ADCY5 silencing (Sup-
plementary Fig. 5B).
GLP-1–Stimulated b-Cell Activity Does Not Involve
ADCY5
Consistent with the lack of effect of gene silencing on
GLP-1–induced insulin release, loss of ADCY5 failed to
impact Ca2+ changes and even appeared to augment Ca2+
increases in response to the incretin without modulating
the proportion of responsive cells (Fig. 4A and B and
Supplementary Movies 3 and 4). Furthermore, GLP-1–
mediated increases in b-cell–b-cell connectivity, critical
for generating the acute (5–10 min) bursts in coordinated
activity that underlie incretin potentiation of glucose-
stimulated insulin secretion (27), were unchanged after
treatment with anti-ADCY5 shRNA (Fig. 4C–E). In line
with this, GLP-1R mRNA expression levels were unaf-
fected by ADCY5 silencing (Fig. 4F).
Glucose Still Increases Cytosolic ATP-to-ADP Ratio
After ADCY5 Silencing
We wondered whether the substantial reductions in
glucose-induced Ca2+ rises and insulin release, detected
in ADCY5-silenced islets, were accompanied by fulminant
changes to b-cell glucose metabolism. To allow the real
time recording of ATP dynamics speciﬁcally in b-cells, the
expression of the recombinant probe Perceval was di-
rected in human islets using an adenoviral vector (6,43).
Conﬁrming tropism of the virus for b-cells, as previously
described in rodent islets (44), green ﬂuorescent protein
ﬂuorescence was restricted to insulin-immunopositive
cells (Fig. 5A). In response to increasing glucose concen-
trations (3–17 mmol/L), b-cells responded with large, co-
ordinated, and nonoscillatory elevations in ATP-to-ADP
ratio (Fig. 5B). Although signiﬁcantly reduced, a glucose-
induced increase in ATP-to-ADP ratio could still be de-
tected after ADCY5 silencing (Fig. 5C). Further excluding
a role for cAMP-independent effects on KATP or voltage-
dependent Ca2+ channel (VDCC) activity, ADCY5 silencing
Table 1—Insulin and proinsulin content in Con and ADCY5
shRNA-treated islets (n = 4 donors)
Con shRNA
Proinsulin content (ng/islet) 0.82 6 0.11 0.93 6 0.07
Insulin content (ng/islet) 32.8 6 3.5 29.8 6 3.1
Proinsulin:insulin (%) 2.6 6 0.5 4.0 6 1.2
Data are means 6 SEM.
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Figure 3—ADCY5 depletion suppresses glucose-induced increases in cytosolic free Ca2+. A: ADCY5 silencing decreases cystosolic cAMP
levels, as determined using the recombinant probe Epac2-camps (representative traces shown; gray/black, smoothed; red, raw). B: As for A,
but summary data showing a reduction in measured FRET signal versus maximal stimulation with FSK (%), as well as decreased AUC (**P <
0.01 vs. Con; Student t test; n = 12 recordings from three donors). C: ADCY5 knockdown suppresses 11 mmol/L glucose (G11)-evoked
cytosolic Ca2+ rises (left panel: mean traces) (right panel: zoom-in of Ca2+ oscillations). D: AUC and amplitude of Ca2+ rises are reduced in
shRNA-treated islets (right panel, **P < 0.01 vs. Con; Mann-Whitney U test; n = 10 islets from three donors). E: Pseudocolored Con and
shRNA-treated human islets during exposure to 11 mmol/L glucose (recording time = 40 min; image cropped to display a single islet). F:
ADCY5 is required for long-term evolutions in coordinated cell activity after exposure to elevated glucose (**P< 0.01 vs. Con; Mann-WhitneyU
test; n = 9–10 islets from three donors) (correlation calculated over 20–30 min; sig, signiﬁcantly). G: Representative functional connectivity map
depicting location, number, and strength (color-coded; 0 [blue] = lowest, 1 [red] = highest) of signiﬁcantly correlated cell pairs (Pearson R
coefﬁcient, P < 0.05). Note that ADCY5 silencing decreases both the number and strength of correlations. H: Gene silencing does not
signiﬁcantly alter the percentage (%) of glucose (11 mmol/L)-responsive cells (NS, nonsigniﬁcant vs. Con; Mann-Whitney U test). I: The
cumulative distribution of Ca2+-spiking frequencies remains similar in Con and shRNA-treated islets. Values represent mean 6 SEM.
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did not alter Ca2+ rises induced by KCl applied in the ab-
sence and presence of the KATP channel opener, diazoxide
(Supplementary Fig. 6A and B). Consistent with our pre-
vious ﬁndings in MIN6 b-cells (12), GLP-1 was able to
provoke signiﬁcant rises in ATP-to-ADP ratio under both
low (3 mmol/L) and high (16.7 mmol/L) glucose conditions
(Fig. 5D–F), as well as in the presence of ADCY5 silencing
(Fig. 5G and H). Hence, an action of glucose to accelerate
oxidative metabolism toward ATP synthesis is not a pre-
requisite for GLP-1 signaling.
Figure 4—ADCY5 does not mediate GLP-1–stimulated cytosolic Ca2+ increases. A: ADCY5 knockdown subtly improves GLP-1 responses
(left panel: mean traces), as evidenced by increased AUC and amplitude of cytosolic Ca2+ rises in shRNA-treated islets (right panel) (**P <
0.01 vs. Con; Mann-Whitney U test; n = 10 islets from three donors). B: The proportion of GLP-1–responsive cells is similar in Con and
shRNA-treated islets (NS, nonsigniﬁcant vs. Con; Mann-Whitney U test). C: ADCY5 silencing does not affect coordinated b-cell responses
to 11 mmol/L glucose plus GLP-1 (representative Ca2+ traces [top panel]; gray, smoothed; red, raw) (heat map depicting minimum–
maximum for each cell [bottom panel]) (n = 10 islets from three donors; correlation measured using 5-min windows). D: Histogram showing
mean % signiﬁcantly correlated cell pairs in Con and shRNA-treated islets before, during, and after GLP-1 application (NS, nonsigniﬁcant;
two-way ANOVA). E: Representative weighted graphs demonstrating large increases in b-cell connectivity after exposure to GLP-1 in both
normal and ADCY5-depleted islets (scale bar, 50 mm). F: Gene silencing does not alter GLP-1R mRNA expression (NS, nonsigniﬁcant vs.
Con; Student paired t test; n = 3 donors). Values represent mean 6 SEM.
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To determine the relative contribution of metabolism to
ADCY5-regulated b-cell function, ATP-to-ADP dynamics
were imaged after exposure to increasing glucose concen-
trations. Whereas both Con and ADCY5-silenced islets
responded normally to 5 and 8 mmol/L glucose (Fig. 6A),
the latter failed to respond to further elevation of the
sugar, and this deﬁcit could be rescued using FSK to elevate
cAMP (Fig. 6B). Cytosolic Ca2+ responses to 8 mmol/L
glucose, however, remained suppressed after ADCY5 knock-
down (Fig. 6C).
DISCUSSION
The aim of the current study was to explore the role of
ADCY5 in the regulation of insulin secretion from human
islets. We show that ADCY5 is required to link glucose-
derived signals to the intracellular Ca2+ rises that princi-
pally drive insulin granule exocytosis. By contrast, incretins
such as GLP-1 remain competent to evoke insulin release
in the face of ADCY5 silencing (Fig. 7). Providing com-
pelling evidence that defective ADCY5 action may con-
tribute to impaired fasting glucose were the observations
that mRNA expression was reduced in islets from sub-
jects harboring risk alleles at rs11708067. Interestingly,
ADCY5 mRNA levels were also reduced in b-cells from
(ungenotyped) patients with T2D versus healthy donors
(33), providing a further link with disease status.
Assessed by next-generation sequencing (RNA-Seq),
ADCY5mRNA occupies the top 13th centile of all mRNAs in
human islets (45) and is the most strongly expressed mem-
ber of the ADCY family in this tissue, with mRNA levels
approximately twofold higher than those of ADCY1, the
next most abundant isoform, and 50% higher than ADCY6
mRNA. Assuming similar levels of PPIA mRNA, our qRT-
PCR results in isolated human islets are broadly consistent
with this observation (Fig. 1A). Of note, however, analysis of
laser-capture–dissected b-cells (33) (Gene Expression Omni-
bus public repository, accession no. GSE20966) and a b-cell–
enriched fraction from human islets (46) revealed lower
levels of ADCY5 mRNA (;50th and ;65th centiles, respec-
tively), being in each case ;50% of those of ADCY6. In-
triguingly, in the current study, Adcy5 mRNA was barely
detectable in mouse islets, being expressed at a level ;40-
fold lower than Adcy6 (Fig. 1). A similar, though less marked
(approximately eightfold), preponderance of ADCY6 over
ADCY5 mRNA also exists for rat islets (47), demonstrating
marked species variability in the relative abundance of
Figure 5—ADCY5 alters b-cell energetics. A: Expression of the
ATP/ADP probe Perceval is predominantly restricted to b-cells, as
shown using immunohistochemistry with antibodies against insulin
and glucagon (scale bar, 25 mm [top panels] and 20 mm [bottom
panels]). B: Glucose (17 mmol/L) (G17) still induces increases in
ATP-to-ADP ratio after ADCY5 silencing (representative traces
shown; gray/black, smoothed; red, raw). C: Bar graph showing a sig-
niﬁcant effect of shRNA treatment on the amplitude of cytosolic (cyt)
ATP/ADP rises in response to 17 mmol/L glucose (*P< 0.05 vs. Con;
Mann-Whitney U test; n = 9–10 islets from three donors). D: GLP-1
increases ATP/ADP in the presence of permissive (17 mmol/L) glu-
cose concentrations (representative traces shown; gray/black,
smoothed; red, raw). E: As for D, but in the presence of nonpermis-
sive (3 mmol/L) glucose concentrations. F: Summary statistics
demonstrate similar effects of GLP-1 on ATP/ADP in islets exposed
to 3 or 17 mmol/L glucose (NS, nonsigniﬁcant vs. Con; Mann-Whitney
U test; n = 10–13 recordings from ﬁve donors). G: ATP/ADP responses
to GLP-1 are similar in Con and ADCY5 shRNA-treated islets
(representative traces shown; gray/black, smoothed; red, raw).
H: Summary statistics demonstrate no signiﬁcant effect of gene
silencing on GLP-1–induced ATP/ADP rises (NS, nonsigniﬁcant vs.
Con; Mann-Whitney U test; n = 6 recordings from two donors). Values
represent mean 6 SEM.
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ADCY isoforms within this tissue. Since these variations do
not appear to reﬂect the greater proportion of a-cells in
human (48) versus rodent (49) islets, ADCY5 may serve a
nonconserved function between mammalian species.
Levels of mRNA encoding ADCY8, previously reported
to be regulated by glucose in rat and human islets (50),
were recently shown to be much lower in human islets
than either ADCY5 or -6 (45). Conﬁrming these ﬁndings,
ADCY8 mRNA was undetectable in four out of the ﬁve
independent repeats that we conducted in human islets,
and in the single experiment in which an amplicon was
present, Ct values were incompatible with accurate quan-
tiﬁcation (37.05 6 0.49 cycles).
Of other genes lying 250 kb on either side of
rs2877716 and rs11708067, which might also conceivably
mediate the observed effects on diabetes risk, MYLK
transcripts are barely detectable in human islets (45,46).
On the other hand, SEC22A, PDIA, and PTPLB are each
detectably expressed and so may contribute. Nonetheless,
our observations on the effects of ADCY5 silencing are
entirely consistent with the observed phenotype of sub-
jects possessing risk alleles (22).
The strong dependence of glucose-stimulated insulin
secretion upon ADCY5 expression in human islets is
surprising given the abundant presence of ADCY6 and the
redundancies inherent to the cAMP signaling cassette
(51). Although the above differences at the mRNA level
are not necessarily reﬂective of protein quantity or enzy-
matic activity, the observed sensitivity to ADCY5 deple-
tion may reﬂect either microcompartmentalization of
ADCY5-containing complexes in proximity to Ca2+ inﬂux
and release sites (52) or a requirement for ADCY5 in
cAMP-independent signaling processes. Thus, while our
data indicate that ADCY5 couples glucose to insulin se-
cretion by translating a glucose signal into cAMP gener-
ation (53), GLP-1 receptors may engage alternative
ADCY family members to modify cAMP dynamics. Fur-
ther studies will be required to explore the latter possi-
bility (Fig. 7). Of note, global deletion of ADCY5 in mice
leads to longevity and the resistance of cardiomyocytes
to oxidative stress via the upregulation of Ras-MAPK
signaling (20). A similar mechanism might therefore
contribute to the small but signiﬁcant enhancement of
GLP-1 signaling observed here in human b-cells after
ADCY5 silencing.
Although ADCY5 is Ca2+ inhibited in vitro (19), the
range of Ca2+ concentrations over which inhibition occurs
(.10 mmol/L) comfortably exceeds normal intracellu-
lar concentrations of these ions in b-cells (8). Whether
ADCY5 is therefore a direct target for activation by intra-
cellular signals generated by glucose (ATP, etc.) or is, rather,
a passive but essential element of a glucose-activated sig-
naling pathway leading to Ca2+ inﬂux and insulin release
remains to be established.
Recent studies have shown that the intraislet regula-
tion of cell-cell communication is critical for the proper
generation of hormone release after secretagogue chal-
lenge (27). Providing further evidence that the islet con-
text is an important player in insulin secretion was the
observation in the current study that b-cell responses to
glucose were less coordinated in islets depleted of ADCY5.
While the mechanisms underlying this phenomenon re-
main obscure, cAMP has been shown to alter b-cell gap
junction conductance (39), and the resultant enhanced
intercellular coupling may contribute to the insulin-
raising actions of cAMP-elevating agents such as glucose
and incretins. Whereas we recently showed that knock-
down of connexin 36 markedly reduced coordinated cell
responses to incretin, more modest effects on glucose ac-
tion were observed (27). The impact of cAMP on glucose-
induced cell connectivity may therefore also stem from
perturbed paracrine signaling circuits between b-, a-,
and other cell types, in addition to enhanced electrotonic
Figure 6—ADCY5 targets nonmetabolic processes to alter Ca2+
responses. A: Impaired ATP/ADP responses are only present in
ADCY5-silenced islets at glucose concentrations of $11 mmol/L
(**P < 0.01 vs. Con; two-way ANOVA; n = 9 recordings from three
donors). B: Elevation of cAMP using FSK rescues ATP/ADP rises in
ADCY5-silenced islets after transition from 3 mmol/L to 17 mmol/L
glucose (G3-G17) (**P < 0.01 vs. shRNA; one-way ANOVA; n = 9
recordings from three donors; n = 4–5 recordings). C: ADCY5
knockdown suppresses b-cell Ca2+ responses after transition
from 3 mmol/L to 8 mmol/L glucose (G3-G8) (representative traces
[left panel]; gray/black, smoothed; red, raw]), as evidenced by re-
duced amplitude (right panel) (**P< 0.01 vs. shRNA; Mann-Whitney
U test; n = 8–9 recordings from three donors).
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coupling. Likewise, an intriguing possibility is that ADCY5
suppression may also affect glucagon and, potentially,
GLP-1 (54) secretion from neighboring a-cells to af-
fect b-cell “glucose competence.” In any case, ADCY5-
depleted islets still displayed impaired Ca2+ responses
even when metabolic dysfunction was accounted for
(Fig. 6B), supporting the view that other downstream
processes, including cell-cell communication, are targeted
by cAMP signaling.
Remarkably, GLP-1 evoked Ca2+ rises and hormone re-
lease even when glucose-stimulated insulin secretion was
abolished by ADCY5 silencing. This implies that GLP-1
signaling—generally believed to hinge on increased intra-
cellular cAMP levels (55)—is sufﬁcient under these con-
ditions to elicit closure of KATP and induce Ca
2+ inﬂux and
exocytosis. Indeed, studies by Miki et al. (56) have dem-
onstrated that GLP-1 is still able to evoke insulin secre-
tion in the complete absence of KATP channels. Thus, the
glucose dependency of GLP-1–induced insulin secretion is
unlikely solely to reﬂect the effects of the sugar on oxida-
tive metabolism and, hence, the closure of KATP channels,
especially in light of data showing the absence of GLP-1–
induced Ca2+ rises in human islets incubated at nonpermis-
sive glucose concentrations (27). Rather than a simple sum-
mation of glucose and GLP-1–derived Ca2+ signals, the
ATP/ADP responses to the latter, readily detectable at
low glucose concentrations, may instead be converted
into a depolarizing stimulus through a complex interplay
between KATP-dependent and -independent pathways (10).
In summary, we describe here a novel role for the
GWAS-identiﬁed gene ADCY5 in the normal regulation of
insulin secretion from human islets of Langerhans. Thus,
we elucidate a pathway that converts ADCY5 gene poly-
morphisms into defective b-cell function. Since b-cell
decompensation is a hallmark of T2D pathogenesis irre-
spective of genotype, ADCY5 may provide a useful target
for the restoration of insulin release in man.
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Figure 7—Schematic of ADCY5 function in human b-cells. Glucose-stimulated insulin secretion relies on KATP-dependent and -independent
signals. The latter include cAMP generation, and this likely requires ADCY5 activation by the sugar to increase ATP generation, Ca2+ inﬂux,
and exocytosis (left panel). By contrast, incretins such as GLP-1, believed primarily to engage cAMP-signaling pathways, may potentiate
insulin secretion via other ADCY isoforms (right panel). PKA, protein kinase A.
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